Myeloma Paper of the Day, October 6th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Study of impact of daratumumab on collection and engraftment in myeloma patients undergoing stem cell mobilization with G-CSF + plerixafor shows daratumumab does not impair HSC collection nor post-ASCT hematopoietic recovery.”

Source: Robert Orlowski/X

Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor

Authors: Giuseppe Bertuglia, Bruno Garibaldi, Andrea Casson, Barbara Sarina, Francesca Gay, Silvio Mercadante, Jacopo Mariotti, Mattia D’agostino, Daniela Taurino, Stefania Oliva, Alessandra Larocca, Daniele Mannina, Chiara De Philippis, Giulia Benevolo, Tiziana Francisci, Marco Lorenzi, Benedetto Bruno, Armando Santoro, Sara Bringhen, Roberto Mina and Stefania Bramanti.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.